Icure(59,000 +1.03%)Announced on the 19th that it has completed the establishment of a constant temperature delivery system that can distribute Corona 19 vaccines and treatments in optimal conditions through the’Cold Chain Consortium’.
Icure is in charge of logistics, distribution and funding, and provides the consortium with quantitative temperature and transportation information for the COVID-19 vaccine and treatment. The companies specializing in cold distribution (cold chain) participating in the consortium are in charge of optimal solutions for constant temperature storage, packaging, and transportation.
The company explained that it has completed consortium contracts and consultations with cold chain companies. One of these is Brings Global, which provides high-quality transportation services for pharmaceuticals.
The company said that Brings’ global Korean branch can set and manage different storage temperatures for each drug, the company said. In order to maintain a frozen state of -20 degrees Celsius, raw materials for protein preparations and plasma, etc., use a temperature-maintaining vehicle, a transport container using a refrigerant, and a refrigeration container. Clinical virus samples and cell therapy products are being transported using dry ice mainly to maintain cryogenic temperatures below -70 degrees Celsius. Products that must maintain cryogenic temperatures below -190 degrees Celsius, such as cell lines and cell therapy products, are transported in nitrogen containers filled with nitrogen.
Icure emphasized that the consortium is capable of cold chain transportation anywhere in Korea through 19 branches operating nationwide.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution